Veracyte (NASDAQ:VCYT) Rating Lowered to “Market Perform” at Leerink Partners

Veracyte (NASDAQ:VCYT) was downgraded by Leerink Partners from an “outperform” rating to a “market perform” rating in a report released on Thursday, Briefing.com reports. They presently have a $35.00 target price on the biotechnology company’s stock. Leerink Partners‘s price target indicates a potential downside of 33.36% from the company’s previous close.

VCYT has been the subject of several other reports. Needham & Company LLC reissued a “buy” rating on shares of Veracyte in a report on Tuesday, September 15th. Morgan Stanley cut their price objective on Veracyte from $47.00 to $44.00 and set an “underweight” rating for the company in a report on Tuesday, August 4th. Weiss Ratings cut Veracyte from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, September 24th. Wall Street Zen cut shares of Veracyte from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 10th. Finally, UBS Group raised their price target on Veracyte from $52.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $53.70.

Veracyte Trading Up 4.4%

Shares of Veracyte stock opened at $52.52 on Thursday. The business’s fifty day simple moving average is $44.90 and its 200 day simple moving average is $43.04. The firm has a market capitalization of $4.22 billion, a P/E ratio of 37.25 and a beta of 1.98. Veracyte has a 12 month low of $29.45 and a 12 month high of $60.91.

Veracyte (NASDAQ:VCYT) last released its earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.10. The business had revenue of $151.75 million during the quarter, compared to the consensus estimate of $147.13 million. Veracyte had a return on equity of 9.26% and a net margin of 20.37%. The business’s revenue for the quarter was up 15.1% on a year-over-year basis. During the same period last year, the business posted $0.51 earnings per share. Analysts predict that Veracyte will post 1.32 EPS for the current fiscal year.

Insider Activity at Veracyte

In related news, Director Karin Eastham sold 14,850 shares of Veracyte stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $50.00, for a total transaction of $742,500.00. Following the transaction, the director owned 10,247 shares in the company, valued at approximately $512,350. The trade was a 59.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John Leite sold 4,015 shares of the business’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $40.00, for a total value of $160,600.00. Following the completion of the transaction, the insider owned 124,329 shares in the company, valued at $4,973,160. The trade was a 3.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 62,609 shares of company stock worth $2,858,904 in the last 90 days. Insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Veracyte

Several institutional investors have recently bought and sold shares of VCYT. Allspring Global Investments Holdings LLC lifted its holdings in shares of Veracyte by 7.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 16,795 shares of the biotechnology company’s stock valued at $742,000 after acquiring an additional 1,121 shares during the last quarter. Candriam S.C.A. lifted its position in shares of Veracyte by 38.1% in the 3rd quarter. Candriam S.C.A. now owns 186,387 shares of the biotechnology company’s stock worth $8,613,000 after purchasing an additional 51,392 shares during the period. Alps Advisors Inc. bought a new stake in Veracyte during the third quarter valued at about $648,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Veracyte in the 3rd quarter worth $388,000. Finally, Provenance Wealth Advisors LLC acquired a new stake in Veracyte in the 3rd quarter worth approximately $292,000.

Veracyte News Roundup

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Veracyte reported Q3 adjusted earnings of $0.51 per share, above analyst estimates of $0.41, and revenue of $151.8 million, topping expectations of about $147.1 million. Revenue rose 15% year over year, including testing revenue of $146.4 million. Veracyte Announces Third Quarter 2026 Financial Results
• Positive Sentiment: The company authorized a $100 million share repurchase program, which may support shareholder returns and signal management confidence. Veracyte authorizes a Buyback Plan
• Positive Sentiment: Analysts’ average price target is reported at $55.78, indicating potential upside relative to the share price cited in the background information. Veracyte Stock Has Average Price Target of $55.78
• Neutral Sentiment: Despite the revenue increase, quarterly EPS matched the year-ago result of $0.51, so earnings growth has not yet reflected the stronger sales. Veracyte Tops Q3 Earnings and Revenue Estimates

Veracyte Company Profile

Veracyte, Inc is a diagnostics company that develops genomic tests to help physicians diagnose cancer, assess disease risk and guide treatment decisions. Its tests are designed to provide additional molecular information from patient samples, often helping reduce uncertainty and support more personalized care.

The company’s portfolio includes Afirma tests for thyroid nodules, Decipher tests for prostate cancer, Percepta tests for lung cancer and Envisio tests for breast cancer. Veracyte also develops and commercializes additional genomic assays intended for use across various cancer types and clinical settings.

Founded in 2008 and headquartered in South San Francisco, California, Veracyte primarily serves the U.S.